Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
DISA ( (SG:532) ) has shared an announcement.
DISA Limited’s subsidiary, Digital Life Line, has initiated a clinical trial for its Automated Visual Acuity Test (AVAT) device at Ng Teng Fong General Hospital. This trial aims to demonstrate the device’s effectiveness in a high-volume community hospital, potentially expanding its market beyond tertiary specialist centers. The AVAT device, which allows patients to self-administer eye exams, has already shown success at Singapore’s National University Hospital by improving workflow efficiency and reducing patient wait times. This strategic move is expected to create a new revenue stream and address the growing demand for ophthalmological services in mainstream healthcare settings.
More about DISA
DISA Limited, incorporated in Singapore, operates in the healthcare technology industry through its subsidiary Digital Life Line Pte. Ltd. The company focuses on developing automated medical devices, with a primary emphasis on visual acuity testing solutions aimed at enhancing efficiency in healthcare settings.
Current Market Cap: S$14.09M
Find detailed analytics on 532 stock on TipRanks’ Stock Analysis page.